Realtime Access Map
Synergistic apoptotic effects of bortezomib and methylstat inhibitor on different multiple myeloma cell lines
Multiple myeloma is one of the common hematological malignancies that affects plasma cells. Bortezomib, proteasome inhibitor, is an anticancer agent used for the treatment of multiple myeloma while methylstat is a demethylase inhibitor having anticancer potential. In this study, we investigated antiproliferative and apoptotic effects of methylstat alone or in combination with bortezomib. We also examined the genes involved in methylstat induced apoptosis. Cytotoxic effects of bortezomib and methylstat on U266 and ARH77 cells were demonstrated by MTT cell proliferation assay. To understand the apoptotic effects of these agents, loss of mitochondrial membrane potential was investigated by JC-1 method while phosphatidylserine localization was investigated by Annexin V assay. Cell cycle analysis in response to Bortezomib and Methylstat alone or in their combination were measured by flow cytometry. Changes in expression profiles of 84 genes underlying apoptosis, cell cycle control, DNA damage repair, and invasion and metastasis in response to Methylstat were determined by PCR Array. Our results demonstrated that both bortezomib and methylstat have antiproliferative and aoptotic effects in a time and dose dependent manner. Combination of bortezomib and methylstat induced apoptosis significantly as compared to any agent alone. In conclusion, we suggest methylstat as candidate agent for the treatment of MM after in vivo analyses.